To direct the Secretary of Health and Human Services, acting through the Commissioner of Food and Drugs, to revise certain regulations related to infant and toddler beverages, and for other purposes.
Direct the Secretary of Health and Human Services to revise regulations related to infant and toddler beverages.
Occurrences
By Ms. JACOBS: H.R. 8412. A bill to direct the Secretary of Health and Human Services, acting through the Commissioner of Food and Drugs, to revise certain regulations related to infant and toddler beverages, and for other purposes; to the Committee on Energy and Commerce.
Ms. Jacobs introduced the following bill; which was referred to the Committee on Energy and Commerce
Evidence
H.R. 8412 is titled "To direct the Secretary of Health and Human Services, acting through the Commissioner of Food and Drugs, to revise certain regulations related to infant and toddler beverages, and for other purposes." GovInfo lists the last action date as April 21, 2026 and says Ms. Jacobs introduced the bill and it was referred to the House Committee on Energy and Commerce.
The Congressional Record for the House includes the entry: "By Ms. JACOBS: H.R. 8412. A bill to direct the Secretary of Health and Human Services, acting through the Commissioner of Food and Drugs, to revise certain regulations related to infant and toddler beverages, and for other purposes; to the Committee on Energy and Commerce."
The House Energy and Commerce Committee announced a Subcommittee on Health hearing for April 29, 2026, and listed H.R. 8412, "No False Formula Act (Rep. Jacobs)," among the bills to be discussed.
The committee repository for the April 29, 2026 hearing lists H.R. 8412, "No False Formula Act," under the text of legislation and shows the hearing record and supporting documents updated through April 30, 2026.
Assessments
Jacobs introduced H.R. 8412, the No False Formula Act, which directly matched the promise by directing HHS/FDA to revise regulations related to infant and toddler beverages. The bill was referred to committee and received hearing activity in April 2026, showing a serious legislative effort during her current House term. However, the evidence does not show enactment, passage, or an implemented HHS/FDA regulatory revision, so the promised outcome was not delivered.